구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv) Johnson & Johnson·BCMA × CD3 132 trials·t½ ~2–3 weeks at steady state | |
|---|---|---|
Overview Program | Tecvayli (teclistamab) | Talquetamab |
Overview Company | Johnson & Johnson | Janssen |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | BCMA × CD3 | FRα |
Overview Indication | Relapsed or refractory multiple myeloma | Myeloma Multiple; Plasma Cell Leukemia |
Overview Phase | APPROVED | PHASE_3 |
Overview Status | APPROVED | DISCONTINUED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma. | first-in-class, T-cell-redirecting bispecific antibody targeting GPRC5D, a novel antigen highly expressed on malignant plasma cells wi |
Positioning Known limitation | BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion. | resistance mechanisms |
Positioning Development positioning | Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T. | — |
MoA Mechanism | Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity. | , Clinical, and Translational Science |
MoA Biomarker | BCMA expression, MRD negativity, serum free light chain response. | BCMA (teclistamab) demonstrated unexpectedly high |
PK/PD Half-life | ~2–3 weeks at steady state | — |
PK/PD Species | Cynomolgus monkey, T-cell activation markers, cytokine profile, soluble BCMA | Cynomolgus monkey, NHP, Mouse, Human |
PK/PD Animal (cat.) | Human, NHP | Human, Mouse, NHP, Monkey |
PK/PD Experiment | pharmacokinetic | pharmacokinetic |
Toxicology Species | Mouse | Cynomolgus monkey, NHP, Mouse, Human |
Toxicology Animal (cat.) | — | Human, Mouse, NHP, Monkey |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | thrombocytopenia was significantly increased in patients with RI |
Toxicology CRS | CRS ~72%, grade ≥3 ~0.6% | Reported |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | thrombocytopenia was significantly increased in patients with RI |
Clinical Selected reported efficacy | ORR 63% | — |
Clinical Reported ORR | 63.0% | — |
Clinical Reported PFS | ~11.3 mo | — |
Clinical Result source | MajesTEC-1 (NCT03145181 / NCT04557098) | — |
Clinical Program phase | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | — |
Clinical Trial ref | NCT03145181 | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv) Johnson & Johnson·BCMA × CD3 132 trials·t½ ~2–3 weeks at steady state | |
|---|---|---|
Overview Program | Tecvayli (teclistamab) | Talquetamab |
Overview Company | Johnson & Johnson | Janssen |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | BCMA × CD3 | FRα |
Overview Indication | Relapsed or refractory multiple myeloma | Myeloma Multiple; Plasma Cell Leukemia |
Overview Phase | APPROVED | PHASE_3 |
Overview Status | APPROVED | DISCONTINUED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma. | first-in-class, T-cell-redirecting bispecific antibody targeting GPRC5D, a novel antigen highly expressed on malignant plasma cells wi |
Positioning Known limitation | BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion. | resistance mechanisms |
Positioning Development positioning | Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T. | — |
MoA Mechanism | Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity. | , Clinical, and Translational Science |
MoA Biomarker | BCMA expression, MRD negativity, serum free light chain response. | BCMA (teclistamab) demonstrated unexpectedly high |
PK/PD Half-life | ~2–3 weeks at steady state | — |
PK/PD Species | Cynomolgus monkey, T-cell activation markers, cytokine profile, soluble BCMA | Cynomolgus monkey, NHP, Mouse, Human |
PK/PD Animal (cat.) | Human, NHP | Human, Mouse, NHP, Monkey |
PK/PD Experiment | pharmacokinetic | pharmacokinetic |
Toxicology Species | Mouse | Cynomolgus monkey, NHP, Mouse, Human |
Toxicology Animal (cat.) | — | Human, Mouse, NHP, Monkey |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | thrombocytopenia was significantly increased in patients with RI |
Toxicology CRS | CRS ~72%, grade ≥3 ~0.6% | Reported |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | thrombocytopenia was significantly increased in patients with RI |
Clinical Selected reported efficacy | ORR 63% | — |
Clinical Reported ORR | 63.0% | — |
Clinical Reported PFS | ~11.3 mo | — |
Clinical Result source | MajesTEC-1 (NCT03145181 / NCT04557098) | — |
Clinical Program phase | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | — |
Clinical Trial ref | NCT03145181 | — |
추천 비교
추천 비교